drugset / Trial / NCT00344994
SWITCH:Restless Legs Patients Switched to Ropinirole From Pramipexole
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the equipotent dose of ropinirole and pramipexole for patients switched from pramipexole to ropinirole in patients with moderate to severe primary Restless Legs Syndrome (RLS). The rationale behind Switch is that patients with Restless Legs Syndrome can maintain stable efficacy and tolerability if correctly switched from one dopamine agonist to an equipotent dose of another.
Timeline
- Start
- 2006-05
- Primary completion
- 2007-09
- Completion
- 2010-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pramipexole | Unknown | 0.25 mg | Oral |
| Subject | Pramipexole | Unknown | 0.5 mg | Oral |
| Subject | Pramipexole | Unknown | 0.75 mg | Oral |